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ABSTRACT 
 
The aim of this thesis was to study high-grade cervical intraepithelial neoplasia (CIN) in women 
living with HIV (WLWH) in Sweden compared with HIV-negative women (HNW) of the same 
region of birth.  
In Paper I we assessed the cumulative incidence (CuI) and hazard ratio (HR) of CIN3, 
adenocarcinoma, and invasive cervical cancer (CIN3+) in a cohort of WLWH (n = 893) and HNW (n 
= 205 842) by linking the Swedish national HIV registry (InfCare HIV) with the Swedish Population 
Registry (SPR) and the Swedish National Cervical Screening Registry (NKCx). The CuI of CIN3+ 
was 13.1% (95% CI 8.9-17.2) and 2.1% (95% CI 2.0-2.2) for WLWH and HNW, respectively. 
WLWH had more than eight times higher risk of CIN3+ than HNW (HR 8.8: 95% CI 6.9–11.3), 
increasing with the level of immunosuppression. The highest risk was seen in WLWH born in the East 
region, dominated by Thai women.  
In Paper II we analysed if the prevalence of undiagnosed HIV in women diagnosed with CIN2+ (n = 
62 874) in the counties of Stockholm and Gothenburg, Sweden, would reach the threshold of 0.1%, 
which has been suggested cost-effective for HIV-testing. The proportion of undiagnosed HIV was 
calculated by linking NKCx with InfCare HIV and did not exceed 0.1% in all women, indicating that 
HIV-testing all women with CIN2+ in Sweden may not be cost-effective. However the proportion of 
undiagnosed HIV exceeded 0.1% among migrant women diagnosed with CIN2+ suggesting that HIV-
testing should routinely be performed in this population.  
In Paper III we assessed outcome after treatment of CIN2+ in 140 WLWH and 284 HNW, matched 
for country of birth, identified by linking NKCx with InfCare HIV and SPR. WLWH were three times 
more likely to have treatment failure (odds ratio (OR) 3.7 [95% CI 2.0-6.8]) and five times more 
likely to recur (hazard ratio 5.0: 95% CI 2.1-11.6) than HNW. Suppressive (HIV-RNA<50 
copies/mL) antiretroviral therapy (ART) at time of treatment of CIN2+ was associated with reduced 
odds ratio of treatment failure (OR 0.3: 95% CI 0.1-0.8).  
In Paper IV we studied whether HPV genotypes in women with CIN2+, identified in paper III, 
differed depending on their HIV status. Cervical tissue blocks of included women were retrieved from 
bio banks and HPV type was identified using modified general primer PCR and Luminex genotyping. 
WLWH were less likely to be infected with HPV 16 (prevalence ratio [PR] 0.6: 95% CI 0.35-0.97), 
and more likely to be infected with multiple high-risk (HR) HPV (PR 2.1, 95% CI 1.17-3.79). Only 
25% of WLWH vs. 47% of HNW had HR HPV types that are covered by the bivalent and 
quadrivalent HPV vaccines (HPV 16 and/or 18) (PR 0.6: 95% CI 0.38-0.97). 
In summary, my thesis showed that WLWH in Sweden are at higher risk of developing CIN3+, have 
poorer outcome after treatment of CIN2+, and less proportion of HPV 16 than HNW. We also found 
level of immunosuppression and, for the first time, suppressive ART to be associated with effective 
treatment of CIN2+. We recommend migrants diagnosed with CIN2+ to be HIV-tested. Early HIV 
diagnosis, access and adherence to ART, HPV vaccination of young people living with HIV and those 
at high-risk of HIV-infection, and finally access and adherence to cervical cancer screening are all 
crucial to minimize the incidence of CIN2+ and its progression to ICC in WLWH. 
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1 PREFACE 
 
As much as I enjoy being an infectious disease clinician, I must admit that nothing beats 
being an HIV-doctor. When I got the opportunity to combine my clinical work with research 
it was very important to me that I would be able to see a connection between those two; my 
clinical work and my research. Also, I wished that, if possible, both my own patients and 
those living with HIV in low and middle-income countries would benefit from our research. 
While most research on HIV is still based on white American males, most of my patients are 
migrant women born in sub-Saharan Africa and Thailand and it was with great satisfaction 
that I joined a project focusing on these women.  
I think that the true joy that working on this thesis has brought me is because I can see my 
patients (anonymously) in every data file, every hazard ratio and every conclusion. It is all 
that I can wish for that these findings might also be a small brick in the building of a healthier 
population living with HIV.  
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2 INTRODUCTION 
 
As an increasing number of people living with human immunodeficiency virus (HIV) 
worldwide are receiving antiretroviral therapy (ART), new problems arise. While access to 
ART has decreased the mortality of acquired immune deficiency syndrome (AIDS) and the 
overall life expectancy is getting closer to that of HIV-negative individuals, cancer 
development is now one of the major threats in this population1-5.  
Persistent infection with carcinogenic human papillomavirus (HPV), so called high-risk HPV 
(HR HPV), is a necessary cause of cervical intraepithelial neoplasia (CIN), which may in turn 
progress to invasive cervical cancer (ICC). Due to HIV-induced immunosuppression, women 
living with HIV (WLWH) are more likely than HIV-negative women (HNW) to have 
persistent HR HPV cervical infections6,7. Consequently, there is an increased global burden 
of ICC, and its precursor high-grade CIN (CIN grade 2 and 3), in WLWH8-11. 
The majority of WLWH diagnosed with HPV-related disease are currently living in low and 
middle income countries (LMIC) where access to cervical cancer screening is often poor11. 
ICC is the most common cancer among women in Eastern and Central Africa and if anything 
the numbers are rising12,13. At the time of the initiation of this thesis there was very little data 
concerning migrants living with HIV who had moved from regions such as sub-Saharan 
Africa (SSA), with the highest incidence of cervical cancer in the world, to a European 
setting with access to better healthcare. There were many unanswered questions such as: Was 
the risk of cervical precancerous lesions higher among migrants living with HIV compared to 
WLWH born in Sweden? Or compared to HNW migrating from the same region? And how 
was their prognosis after treatment of high-grade CIN? Do migrants living with HIV share 
the same HPV-genotypes, which have implications for HPV vaccination and HPV triaging, 
as Swedish-born WLWH or rather the same as HNW from the same region of birth? The 
studies of this thesis focus on these questions. 
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3 BACKGROUND 
 
3.1 HIV 
 
HIV is a lentivirus within the Retroviridae family that is composed of two copies of a 
single-stranded RNA and surrounded by a lipid bilayer membrane derived from the infected 
human host cell14. Two different HIV types, HIV-1 and HIV-2, can infect humans of which 
the latter is mainly seen in a few West African countries, France, Portugal and former 
Portuguese colonies. HIV-2 is therefore not the focus of this thesis. HIV-1 is 
phylogenetically classified into several groups, where the M (major) group, representing 
>90% of all HIV infections, can be further subdivided into nine subtypes (A-D, F-H, J, K) 
and a larger number of circulating recombinant forms15. Subtype C predominates in sub-
Saharan Africa and India while subtype B until now has dominated in Western Europe and 
the US, but with migration this distribution is changing16. 
The virus infects host cells, most importantly CD4+ T-lymphocytes (CD4-cells), by attaching 
to the CD4 receptor and one of the co-receptors CCR5 or CXCR4 (Figure 1). Through the 
use of the viral enzymes reverse transcriptase and integrase, double-stranded DNA is 
generated from the viral RNA templates and integrated into the human genome, thus 
establishing a viral reservoir. A high replication rate, together with the fact that the enzyme 
reverse transcriptase is prone to making mistakes, a large viral load with great diversity is 
developed17. 
 
Figure 1. Life cycle of HIV18. 
Within one to four weeks after infection a (most often) flu-like illness may appear, known 
as primary HIV infection, which may last up to a month. Viral replication peaks about one 
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month after infection and is followed by a period of asymptomatic chronic infection with 
lower viral replication but with a progressive loss of CD4-cells (Figure 2). If an HIV-
infected individual is not treated with ART the CD4-cells will continue to decrease, leading 
to immunosuppression. Typically, HIV-associated diseases, such as oral candidiasis or 
herpes zoster, will appear once the CD4+ T-lymphocytes/µl (CD4 count) is below 350 
(normal range 490-1340). AIDS defining conditions, such as tuberculosis and pneumocystis 
pneumonia, may also appear, especially when the CD4 count is below 200. On average it 
takes 8-10 years from infection to AIDS in untreated individuals19.  
 
Figure 2. Time course of HIV infection in an untreated individual18.  
 
Once an HIV-infected individual has started adequate ART, the HIV replication is 
suppressed and the plasma viral load decreases to concentrations below the lower limit of 
detection (i.e. suppressive ART, defined as < 50 or <20 HIV RNA copies/mL plasma, 
depending on the method used), in most people within six months (Figure 3). This leads to 
a halt of further destruction of the immune system, although a chronic immune activation 
and inflammation remains (more on that below). Some people, especially those who start 
ART at very low CD4 counts, have an impaired CD4 T-cell recovery despite virological 
suppression. This is associated with an increased risk of non-AIDS-related morbidity and 
mortality20,21. 
 
Figure 3. Individual with untreated HIV (>109 infected cells and virions produced and cleared every day), 
ART-treated HIV (low, often undetectable, viral loads but HIV persists in latently infected cells) and ART-
discontinued HIV22.  
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The increasing availability of ART has greatly reduced mortality and morbidity in people 
living with HIV (PLWH) and life expectancy is getting closer to that of the HIV-negative 
population, especially if HIV diagnosis is early23-25. In addition, PLWH who are on 
suppressive ART with undetectable virus in plasma do not transmit the virus26,27. 
3.1.1 HIV-ASSOCIATED IMMUNE ACTIVATION AND INFLAMMATION  
HIV-infection is associated with activation of both the innate and adaptive parts of the 
immune system. At the time of HIV-transmission an extensive systemic immune activation is 
initiated, never to subside completely and even patients with suppressive ART are found to 
have a remaining chronic immune activation and thus low-grade inflammation28.  
The depletion of CD4-cells is partly due to apoptosis of HIV-infected cells, but the majority 
of CD4-cells die of caspase-1 mediated programmed cell death (pyroptosis). While 
pyroptosis may be effective in an acute bacterial infection, it unfortunately has a 
detrimental effect in the pathology of HIV-infection. The release of pro-inflammatory 
cytokines secondary to pyroptosis creates a pathogenic vicious cycle in which dying CD4-
cells release inflammatory signals that attract more cells into the infected lymphoid tissues 
with increased chronic inflammation and tissue injury as a consequence29. 
Microbial translocation through the gut-blood barrier has been found to be an important 
inducer of HIV-associated immune activation. It is caused by damage to the mucosal gut 
barrier which starts already at time of primary HIV-infection due to depletion of CD4-cells 
from gut associated lymphoid tissue. Translocation of bacterial products across the damaged 
gut barrier activates macrophages and dendritic cells to produce pro-inflammatory cytokines 
that keeps the immune system activated30. The chronic inflammation thus seen even in 
patients with suppressive ART, which can be measured by increased levels of pro-
inflammatory biomarkers such as CRP, IL-1, IL-6, and TNF-α, is considered to be associated 
with an increased risk of cardiovascular, neurocognitive and not the least malignant disease31. 
3.1.2 HIV AND CANCER  
PLWH have an increased risk for many cancers compared to the HIV-negative population, 
most importantly virus-related cancer32,33. This is due to HIV-induced immunosuppression 
causing impaired control of oncogenic viruses such as HPV, Epstein-Barr-virus, Human-
herpes-virus-8, Hepatitis C and Hepatitis B8. HIV-associated chronic inflammation and 
environmental/life-style factors may also influence the increased risk of cancer seen in 
PLWH34.  
Cancers in PLWH are defined as AIDS-defining (ADC) (Kaposi sarcoma, non-Hodgkin’s 
lymphoma and cervical cancer) and non-AIDS-defining (NADC) cancers. With access to 
suppressive ART and increasing longevity in PLWH the excess cancer burden has shifted 
from ADCs to NADCs3,4. While an impressive decline has been seen for Kaposi’s sarcoma 
and non-Hodgkin’s lymphoma the effect of ART on ICC has not been as clear (more on that 
below). Virus-related cancers dominate among NADCs together with lung cancer, the latter 
seems to be increased in PLWH even after adjusting for smoking32.  
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3.1.3 EPIDEMIOLOGY OF WOMEN LIVING WITH HIV 
While the global prevalence of HIV is increasing because people on ART are living longer, 
the global incidence is decreasing. It is estimated that there are 36.7 million (30.8-42.9 
million) PLWH in the world today of whom about half, 17.8 million (15.4-20.3 million) are 
women (15+ years old) (Figure 4). Approximately 80% of WLWH reside in SSA, 10% in 
Asia and Pacific, 4% in Eastern Europe and Central Asia and 3% in Western and Central 
Europe and North America35.  
 
Figure 4. Global distribution of women living with HIV (prevalence)36.  
Even though new HIV-infections have declined globally by 11% among adults (women and 
men) and by 47% among children (girls and boys) since 2010, young women remain at an 
unacceptably high risk of HIV in high-prevalence settings. Adolescent girls and young 
women (15–24 years old) accounted for 20% of new HIV-infections among adults worldwide 
in 2015, despite representing just 11% of the adult population35,37.  
3.1.4 WOMEN LIVING WITH HIV IN SWEDEN 
As of April 2018 there were 7536 individuals receiving care for HIV-infection in Sweden of 
whom 2926 (39%) were women. Of these women, 466 (16%) were born in Sweden and 2460 
(84%) were migrants. Almost all women (96%) were on ART and of these practically all 
(97%) had suppressive ART at the time of the last measurement and a vast majority (87%) 
had a CD4 count >350, altogether indicating an exceptionally well-controlled HIV-cohort. In 
fact, Sweden was the first country to reach the 90-90-90 goal of UNAIDS; 90% of estimated 
HIV infected are diagnosed, 90% of diagnosed are on ART and 90% of those on ART are on 
suppressive treatment38,39. 
Almost half (47%) of WLWH in Sweden have at one point been severely immunosuppressed 
with a CD4 nadir (lowest CD4 count ever measured for that individual) below 20040. Over 
the years the epidemiology of the female HIV-population in Sweden has changed with a 
decrease of those infected by intravenous drug use (IVDU) and an increase of heterosexually 
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infected migrants, in particular women born in SSA and South-East Asia41. Today 7% of 
WLWH in Sweden are presumed to be HIV-infected due to IVDU40.  
3.1.5 LATE HIV PRESENTATION  
Of PLWH in the European Union and the European Economic Area (EU/EEA) one in seven 
are estimated to be unaware of their diagnosis and approximately half of all PLWH are 
diagnosed late (i.e. having a CD4 count below 350 cells/mm3 or AIDS at time of HIV-
diagnosis)42,43. A Swedish study from our research group found that more than half of newly 
diagnosed patients were late presenters and that this was associated with higher age and 
migrant status44.  Similarly, being a female migrant from LMIC is associated with late 
presentation in the EU/EEA45. Late HIV-diagnosis has serious consequences and is 
associated with higher mortality, morbidity, high risk of HIV-transmission and increased 
healthcare costs42,46,47.  
To prevent late HIV-diagnosis optimized HIV-testing is essential. Universal HIV-screening 
has been estimated to be cost-effective when the prevalence of undiagnosed HIV in a certain 
population reaches the threshold of 0.1%48-50. A European multicentre study found that eight 
diseases, including cervical or anal cancer/dysplasia, were associated with a prevalence of 
undiagnosed HIV above 0.1%. Consequently, HIV-testing was recommended for individuals 
presenting with these diseases, so-called indicator guided HIV-testing51-54.  
Although HIV-testing is recommended when women with unknown HIV status are 
presenting with high-grade CIN, this seems not to be generally performed. At the time of the 
initiation of this thesis, the prevalence of undiagnosed HIV among women diagnosed with 
high-grade CIN in a low HIV-endemic setting, such as Sweden, was unknown. 
3.2 HUMAN PAPILLOMAVIRUS 
Human papilloma virus is a DNA virus from the papillomavirus family. In the human body 
the virus is most commonly found where there is a transition between squamous and 
glandular cells in the epithelium (squamocolumnar junctions) such as in the cervix, anus and 
tonsils55.  
 
Figure 5. HPV 16 structure and viral proteins56. 
HPV consists of circular double-stranded DNA surrounded by a protein shell composed of 
two proteins (L1 and L2). Only one strand of the double stranded DNA serves as a template 
for transcription. It contains three genomic regions; the early region (E) encodes viral 
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regulatory proteins, the late region (L) encodes the two capsid proteins and the upstream 
regulatory region (URR) contains the origin of the DNA replication and transcription control 
sequences (Figure 5)57.  
HPV is, contrary to HIV, genetically very stable. E6 and E7 are the primary HPV oncogenes 
due to their ability to inhibit essential steps in the human cell cycle. Among other cellular 
targets the oncogene E6 inhibits apoptosis through the inhibition of P53 while the oncogene 
E7 cancels cell-cycle arrest by inhibiting retinoblastoma tumour suppression protein (pRB). 
This may lead to genomic instability, loss of cell-growth control and eventually cancer 
development55,56. 
Classification of HPVs is based on DNA sequence homology, more specifically on the 
nucleotide sequence homology of the L1 gene as this is the most conserved region of the viral 
genome. Within the family Papillomaviridae there are five different genera (alpha, beta, 
gamma, mu and nu) and to date 221 different HPVs have been classified (Figure 6)58,59.  
Alpha papillomaviruses infect epithelial cells in genital mucosa and among these 13 
genotypes constitute the HR HPVs; the carcinogenic group 1: HPVs 16, 18, 31, 33, 35, 39, 
45, 51, 52, 56, 58, 59 and the probably carcinogenic group 2A: HPV 68. Nine HPVs are 
classified as possibly carcinogenic (group 2B: HPVs 26, 30, 53, 66, 67, 69, 70, 73, 82)60,61.  
Benign HPV may cause genital condyloma, most commonly HPV 6 and 11. HR HPV types 
16 and 18 are together estimated to cause around 80% of ICC worldwide60,62 (Figure 7). In a 
large Swedish population-based study with 2850 cases of ICC the most common HR HPV 
type was HPV 16 (60%), followed by HPV 18 (19%), HPV 45 (7%) and HPV 31 (3%)63. 
HPV is mainly transmitted during sexual activity and is the world’s most common sexually 
transmitted infection with about 80% of the world’s female population being infected at some 
point in life. An HPV infection is generally cleared within 12-24 months, but approximately 
10% of women fail to clear the virus and the HPV infection becomes persistent64. In the 
cervix, HPV infects basal cells in the epithelium and it then uses the differentiation of the 
epithelium to move upwards, shedding virions at the cervical surface (Figure 6).  
 
Figure 6. HPV infection and different potential cervical intraepithelial lesions (adapted) 56.  
Normal cervix      CIN1         CIN2                CIN3               Invasive cancer 
Human papillomavirus 
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Persistent infection of the cervical transformation zone with HR HPV is a necessary, but not 
sufficient, cause of ICC and its precursors CIN grade 1-3 (CIN3 equals cancer in situ). CIN is 
the term generally used for histology confirmed lesions while for cytology confirmed lesions 
the term generally used is squamous intraepithelial lesion (SIL) which is further divided into 
low-grade (LSIL) or high-grade (HSIL)56. In Sweden, the nomenclature has recently been 
changed, now using LSILcyt/HSILcyt and LSILhist/HSILhist, but for this thesis the term 
CIN is used for histology confirmed lesions65. 
3.2.1 HIV AND HPV  
WLWH have higher prevalence and cumulative incidence of HPV and are more likely to 
have persistent HR HPV infections than HNW66-68. A global meta-analysis found much 
higher prevalence of HPV (41%) in normal cervical samples in WLWH than what was seen 
in similar samples of HNW (12%) in an earlier study69,70. HPV prevalence is highest in 
WLWH living in Africa and Latin America, but differences compared to other regions 
decrease with increasing severity of lesions69. In women diagnosed with CIN3/ICC, more 
than 90% are HR HPV-positive independent of HIV-status. 
Although HIV and HPV are both sexually transmitted viruses studies, where lifetime sexual 
history was accounted for, have shown that the higher risk of persistent HR HPV-infection 
seen in WLWH compared with HNW is not only due to higher risk of exposure, such as 
number of sexual partners66,71,72. Rather, the difference seen between WLWH and HNW 
mainly seems to be due to HIV-induced immunosuppression, which is believed to cause less 
efficient HPV clearance and perhaps reactivation of latent HPV. Consequently, the 
prevalence and cumulative incidence of HR HPV increases with the level of HIV-induced 
immunosuppression, as expressed by a decreased CD4 count66,73-77. De Vuyst et al. were one 
of the first to show, even though some earlier studies had indicated the same, that ART use is 
associated with a lower prevalence of HR HPV compared to WLWH not on ART and this 
has later been confirmed in a meta-analysis78,79. 
A number of studies have shown a broader range of HPV types in WLWH and these women 
have been found to have a lower relative prevalence of HPV 16 in normal cervical 
cytology69,73,80-82. It has been suggested that HPV 16 is the type which best evades a 
competent immune system, but that with increasing immunosuppression the fraction of non-
HPV 16 genotypes (i.e. 18/31/33/35/39/45/51/52/56/58/59/68) increase among persistent HR 
HPV infections83. Whether this is true for normal/low-grade lesions only has been debated 
but later studies indicate that, as in HNW, genotypes 16, 18 and 45 are the most commonly 
detected in ICC in WLWH although the proportion caused by HPV 16 is significantly 
lower84.  
Multiple HPV infections seem to result from independent events and have been suggested to 
be a biomarker for susceptibility to HPV infection85. WLWH are significantly more prone to 
have multiple HPV infections than HNW, increasing with the severity of immunosuppression 
but decreasing with severity of lesions73,86. The clinical significance of multiple infections is 
unclear as prospective evidence is limited86,87. Testing for HPV from biopsies rather than 
from cervical cytologies is known to reduce the prevalence of multiple infections, however, 
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previous studies of HPV types present in WLWH are, unlike data in this thesis, mostly from 
cervical cytologies69,84,88.  
3.3 INVASIVE CERVICAL CANCER AND ITS PRECURSOR CIN 
As mentioned earlier, persistent HPV infections may lead to malignant transformation of the 
cervix uteri. The initial lesions, CIN1 and CIN2, may resolve spontaneously or progress to 
CIN3 (i.e. cancer in situ) and further to ICC. Typically, it takes 2-5 years from the detection 
of HR HPV to the development of CIN3 and it is estimated that about 30% of these progress 
to ICC within 10 years89. Known risk factors for the development of ICC are smoking, use of 
oral contraceptives, multi parity and immunosuppression56,90,91. Of the global burden of ICC 
almost all are squamous cell carcinomas (about 80%), and the remainder are 
adenocarcinomas (about 10%) or so called “rare types of ICC” (about 5%), but with some 
regional variability92.  
ICC is the fourth most common cancer in women globally, the second most common in SSA 
(age-standardized incidence rates above 30/100 000) and the most common in women in 
Eastern and Middle Africa11,12. Annual incident cases worldwide are estimated to 528 000 
cases (85% in LMIC) and 266 000 deaths (nine in ten in LMIC) worldwide12.  
3.3.1 ICC AND CIN IN WOMEN LIVING WITH HIV 
WLWH have a substantially increased risk of developing CIN2/CIN3 and ICC compared to 
HNW8-10,93. Although ICC was classified as an AIDS-defining disease as early as in 1993, it 
was not until much later it was actually proven to be more common in WLWH than in the 
HIV-negative population1,9,94-98. 
In WLWH, similar to HNW, persistent HR HPV infection is essential for this development 
and consequently WLWH who are HR HPV negative with normal cytological findings have 
similar low risk of developing CIN2+/CIN3+ as do HNW99. On the other hand, WLWH who 
test positive for HPV 16 despite a normal cervical cytology have a higher risk of developing 
CIN2+/CIN3+ than do HNW, especially those immunosuppressed at the time of testing HPV 
16 positive100 
The main risk factor for the development of CIN and ICC in WLWH is 
immunosuppression1,101. A low CD4 nadir or low current CD4 count are both associated with 
an increased risk of CIN2+79,102-104. If this is mainly due to the reduced ability of the 
immunosuppressed woman to clear HPV or if the oncogenic process is enhanced in other 
ways is unclear. An increased risk of CIN2+/ICC is also seen in women who are 
immunosuppressed for other reasons than HIV, for example solid transplant recipients8,105,106.  
The effect of ART on the progression/regression of cervical lesions has until recently been 
unclear as studies have shown conflicting results. The currently best way to determine if ART 
is effective or not is to measure HIV-RNA levels. Unfortunately, most studies performed in 
this field have not had access to HIV-RNA levels and have therefore had to rely on self-
reported ART use as a measure of effective ART, which may have led to reporting bias. 
Additionally, several studies have not adjusted for CD4 nadir, current CD4 count, or time on 
ART, which may explain why the association between ART and progression/regression of 
cervical lesion has remained uncertain for so long107,108.  There are studies, however, 
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adjusting for CD4 count and time on ART that have shown an association between ART and 
outcome of CIN and recently a meta-analysis confirmed reduced incidence of HSIL/CIN2+, 
decreased progression of SIL, increased SIL/CIN regression and reduced incidence of ICC 
among women on ART78,103,109-111.  
The dramatic decline seen for other ADCs (as mentioned above) when ART became 
available was initially not seen for ICC34. This is mainly believed to be due to increased life 
expectancy, essentially suggesting that before ART was available WLWH died of other 
AIDS-associated diseases that progress quicker than ICC. Registry studies in high-income 
countries now suggest a reduction of ICC in WLWH but in regions such as Eastern and 
Central Africa the incidence is increasing13,32,98. 
3.4 TREATMENT OF ICC/CIN IN WOMEN LIVING WITH HIV 
Women with cervical cancer and its precursor CIN are recommended the same treatment 
irrespective of HIV status112. CIN1 is usually a self-healing lesion and is generally treated 
with expectancy only. CIN2 and CIN3 are most often treated with conization. Conization is a 
surgical procedure, which can be performed with local anaesthesia, where a cone-shaped 
wedge that includes the transformation zone and part of the endocervical canal is excised 
from the cervix uteri. Conization may be performed with an electrosurgical loop (LEEP; loop 
electrosurgical excision procedure or LLETZ; large loop excision of the transformation 
zone), which is presently the most common procedure, with cold knife conization or with 
laser. 
Persistence and recurrence of CIN2/3 after treatment with conization is more common in 
WLWH and increases with the level of immunosuppression104,110,113,114. It is unclear if 
WLWH on ART have better outcome after conization than those not on ART as data is 
limited. A majority of studies previously performed have been based on self-reported use of 
ART as a measure of effective ART104,110,115.  
Early stages of ICC are treated with hysterectomy, which is the surgical removal of the 
uterus. Locally advanced disease is most often treated with radio chemotherapy and for 
metastatic disease the treatment is usually palliative112,116. Mortality and relapse after 
treatment of ICC seems to be increased in WLWH, at least in LMIC but clinical data on 
WLWH and outcome after cervical cancer diagnosis is still scarce117-119.  
3.5 CERVICAL CANCER SCREENING 
Cervical cancer screening has earlier been based on regular cervical cytology testing where 
the exfoliated cells from different CIN stages can be detected through microscopic 
examination. The detection and subsequent treatment of CIN abnormalities form the basis of 
the cervical cancer screening programs that have substantially decreased the incidence of ICC 
in high-income countries60,120. Unfortunately, cervical cancer screening coverage is still poor 
in many LMIC121. HPV-PCR-triaging has been gradually introduced in screening programs 
worldwide, though mainly in high-income-countries and in Sweden since 2017. For many 
countries, including Sweden, it is now recommended that women between the ages of 23 and 
29 are tested with cervical cytology every three years, that women between 30 and 49 are 
tested for HR HPV every three years (with a complementing cervical cytology at the age of 
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41) and that women between 50 and 64 are tested for HR HPV every seven years122. For this 
thesis data is based on women who were recommended (if HIV-negative) cervical cytology 
testing every three (aged 23-50) to five years (aged 51-60)112. 
3.5.1 CERVICAL CANCER SCREENING IN WOMEN LIVING WITH HIV 
WLWH who have been adherent to regular cervical cancer screening (every six months in a 
US-based study and annually in a Danish-based study) do not have an increased incidence of 
ICC compared to HNW in studies with long-term follow-up123,124.  
Until recently most high-income countries recommended WLWH to be screened with 
cervical cytology twice during the first year after HIV-diagnosis, followed by annual testing 
until the age of 60. This has also been the recommendation in Sweden for the time period 
included in this thesis. HPV-based screening in WLWH has not been recommended due to 
the high HPV prevalence in WLWH. 
With increasing knowledge concerning HPV and HIV co-infection more guidelines are now 
leaning towards having the same/or more similar HPV-based screening programs for women 
independent of HIV-status65,112,125-127.  This may reduce both under screening and over 
screening in WLWH128.  While the consequences of under screening are clear, over screening 
is associated with an increased risk of pre-term birth (due to repeated conization) and 
increased anxiety in affected women129. 
3.6 HPV VACCINATION 
The HPV vaccine is based on the fact that the structural HPV protein (L1) is able to self-
assemble into immunogenic virus-like particles. The vaccine induces neutralizing antibodies 
that prevent primary infection of the basal layer by binding and presenting HPV antigens to 
the cellular immune system thereby neutralizing the virus and creating a cellular memory130.  
 
Figure 7. HPV genotypes included in current HPV vaccines and high-risk HPVs not covered in current 
HPV vaccines. 
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Initially there were two HPV vaccines, the 2-valent (bivalent) covering HPV 16 and 18 and 
the 4-valent (quadrivalent) vaccine covering HPV 6, 11, 16 and 18 (Figure 7). Later a 9-
valent (nanovalent) vaccine, covering HPV 6, 11, 16, 18, 31, 33, 45, 52 and 58, was 
launched. This is currently being used in HPV vaccination programs in some countries, such 
as the US and New Zealand130,131. All three vaccines have been proven safe and efficacious 
against 6-month persistent cervical infections of HPV 16 and HPV 18 and associated 
precancerous lesions and are equally recommended by the World Health Organization 
(WHO)132-134. The 9-valent may be cost-effective depending on the price of the vaccine and 
the setting131. Cross-protection against types 31, 33 and 45 has been seen for the 2-valent 
vaccine, more limited against type 31 for the 4-valent vaccine and it seems that high 
vaccination coverage is needed for cross-protection to appear133,135.  
To date, 82 countries have introduced HPV vaccination of girls (9-14 years of age) in the 
national immunization programs with a mean vaccine coverage of 61% in those 52 countries 
with available data136. In Sweden, girls between the ages of 9 and 13 have been offered the 4-
valent vaccine since 2012, with a current vaccine coverage of around 80%. In September 
2018, it was decided that the 4-valent will now be exchanged for the 9-valent vaccine in 
Sweden. Vaccination of boys is not yet included in most national vaccination programs and 
whether this addition is cost-effective is still debated, especially where coverage of girls is 
above 80% as herd immunity is then assumed to cover boys too131. Adding boys to the 
vaccination program has been estimated cost-effective in the Swedish program but has not 
yet been implemented137. 
3.6.1 HPV VACCINATION IN PEOPLE LIVING WITH HIV 
Both 2-valent and 4-valent HPV-vaccines have been found to be safe and well tolerated in the 
population living with HIV and do not alter the CD4 counts or HIV viral loads of those 
vaccinated138-141. The rate of seroconversion is similar in PLWH on suppressive ART and 
HIV negative individuals138,142,143. Low CD4 counts seem to be associated with a lower 
antibody titer response but data is limited and the clinical implication of this is unknown, as 
the protective titers of HPV antibodies are not defined142,144. Data regarding HPV vaccine 
efficacy in the HIV-infected population is scarce145. 
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4 AIM 
 
General aim 
To study high-grade cervical intraepithelial neoplasia in women living with HIV in Sweden 
compared with HIV-negative women of the same region of birth. 
Specific aims 
Paper I 
• To assess the cumulative incidence, incidence rate and risk of CIN3+ in women living 
in Sweden, depending on HIV-status, frequency-matched for age and region of birth. 
Paper II 
• To analyse whether the prevalence of undiagnosed HIV in women diagnosed with 
CIN2+ in Sweden reaches the level suggested cost-effective for HIV-testing. 
• To determine if the prevalence of undiagnosed HIV in migrant women diagnosed 
with CIN2+ in Sweden reaches the level suggested cost-effective for HIV-testing. 
Paper III 
• To study the outcome after treatment of CIN2+, depending on HIV-status and 
controlled for country of birth. 
• To assess the predictors of treatment failure and recurrence, after treatment of CIN2+, 
in women living with HIV. 
Paper IV 
• To identify HPV-genotypes associated with CIN2+ in women living in Sweden, 
depending on HIV-status and controlled for country of birth. 
• To determine the proportion of cases of CIN2+ that current HPV vaccines might have 
prevented, depending on HIV status and controlled for country of birth. 
  
  18 
5 METHODS  
 
Table 1. Summary of methods of included papers. 	 Study	design	 Final	study	
population	
Data	
collection	
Main	outcome	 Data	based	on:	
Paper	
I	 Cohort	 WLWH:	893	HNW:	205	842	 1993-2011	
Absolute	risk	of	CIN3+	(cumulative	incidence	and	incidence	rate)		Relative	risk	of	CIN3+	in	WLWH	compared	to	HNW	(hazard	ratio)	
Registry	linking	
Paper	
II	 Case-control	
	Case	(CIN2+):	62	874	Control	(no	CIN2+):	897	703		 1990-2014	 Proportion	of	undiagnosed	HIV	in	women	with/without	CIN2+	
	Registry	linking			
Paper	
III	
Matched	cohort	 WLWH:	140	HNW	284	 1983-2015	
Treatment	failure	after	treatment	of	CIN2+	(odds	ratio)			Recurrence	after	treatment	of					CIN2+	(hazard	ratio)	
Registry	linking		Medical	record	review		
Paper	
IV	 Case	only	 interim	analysis	 1983-2014	 HPV-genotype	detected	in	CIN2+	biopsies	(prevalence	ratio)	
Registry	linking		HPV-genotyping			
Abbreviations: CIN3+: cervical intraepithelial neoplasia grade III, adenocarcinoma in situ and cervical cancer, CIN2+: cervical intraepithelial 
neoplasia grade II, grade III, adenocarcinoma in situ and cervical cancer, HNW: HIV-negative women; WLWH: women living with HIV 
 
5.1 DATA SOURCES AND STUDY POPULATION 
 
Registries used in this thesis 
The Swedish National HIV Registry (InfCare HIV) 
This registry includes > 99% of living Swedish residents diagnosed with HIV. Patients are 
consecutively enrolled to the registry at time of HIV diagnosis and demographic, therapeutic, 
and laboratory data are registered at least every six months38,40. InfCare HIV was established 
in 2003 and the implementation was finalized in all HIV care centres by 2008. Data regarding 
patients diagnosed before 2003 has been complemented retrospectively. Data quality and 
coverage is assessed regularly. For this thesis we extracted data regarding ART, HIV-RNA 
levels, CD4 counts, date of HIV-diagnosis, mode of HIV-transmission and country of birth. 
The Swedish National Cervical Screening Registry (NKCx) 
The NKCx includes all cervical cytology and histology reports in Sweden146. The 
completeness of the register is high, ≥ 90%, for both cytologies and histologies. Evaluation of 
data delivery and coverage is carried out annually. For some regions, screening data has been 
included since the 1960ies and the registry has had national coverage since 1993. For the 
counties of Stockholm and Gothenburg, from which the study populations in this thesis are 
based, data is complete since before 1990. For the women included in this thesis, all cervical 
cytology and histopathology reports of were collected. 
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The Swedish Population Registry 
The Swedish Population Registry (SPR) is maintained by the Swedish Tax Agency and it has 
records of all individuals residing in Sweden on a permanent basis. This registry includes data 
on births, immigration and emigration, deaths, marriages, divorces and changes of 
citizenship. At the time of birth or immigration the individual is assigned a personal 
identification number (PIN). For this thesis data was collected regarding date of birth, date of 
death, date of immigration or emigration and country of birth147. 
Registry linkage procedure  
For all studies in this thesis we used the unique PIN assigned to all individuals in Sweden at 
birth or on immigration to link some (Paper II) or all (Papers I, III and IV) of above 
mentioned registries.  
Study population 
In Paper I the study population consisted of all WLWH (n = 1284) who were alive and 
resident in the County of Stockholm at some point between 1993 and 2011 and HNW (n= 
262 580) living in the same county during the same time period, frequency matched on age 
and region of birth. After inclusion criteria had been met (see paper I for details) the final 
study population included 893 WLWH and 205 842 HNW, between the ages of 18 and 60 
years, with no prior history of cervical cancer and at least one registered cervical cytology or 
biopsy in the NKCx. 
In Paper II the study population consisted of all women born between 1940 and 1990, 
residing in the counties of Stockholm or Gothenburg at some point between 1990 and 2014, 
with at least one cervical cytology or histology registered in the Swedish National Cervical 
Screening Register (NKCx) (n = 960 577) (Table 2).  
Table 2. Paper II. Study population.  
 
a) At least one normal/mildly abnormal (cervical intraepithelial grade 1/atypical squamous cells of undetermined significance/atypical 
glandular cells/atypical cells of uncertain origin) cervical cytology/histology registered in the NKCx. b) At least one diagnosis of CIN2+ 
(cervical intraepithelial neoplasia grade 2, grade 3 adenocarcinoma in situ and invasive cervical cancer) registered in the NKCx. c) According 
to UNAIDS definitions.  
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In Papers III and IV the study population consisted of all WLWH born between 1942 and 
1989, living in the counties of Stockholm and Gothenburg sometime between 1983 and 2014 
and diagnosed with CIN2+ (n = 179) and HNW as controls. For each WLWH, two HNW, 
living in the same counties sometime between 1983 and 2014, diagnosed with CIN2+ (n = 96 
727), were randomly selected and matched for country of birth (n = 321) (Figure 8). For some 
WLWH, only one or no HNW from the same country of birth could be identified and a HNW 
from a neighbouring country was chosen instead. Some HNW matched to more than one 
WLWH. 
 
Figure 8. Flow chart of study population in paper III and IV. 
The final study population for Paper III consisted of 140 WLWH and 284 HNW, born 
between 1942 and 1989, randomly matched for country of birth, living in the counties of 
Stockholm and Gothenburg sometime between 1983 and 2014, treated for histology-verified 
CIN2+, with at least one follow-up cervical cytology/histology within one year and no 
hysterectomy performed before start of follow-up.  
The final study population for Paper IV was not finalized at the time of printing this thesis. 
The interim analysis included 68 WLWH and 127 HNW, born between 1942 and 1989, 
randomly matched for country of birth, living in the counties of Stockholm and Gothenburg 
sometime between 1983 and 2014, with histology-verified CIN2+ and valid HPV-PCR result. 
 
Medical record review 
For Paper I we reviewed 100 randomly selected medical records of included WLWH to 
assess whether there was an underreporting of cervical cytology in the NKCx for these 
 		
 						 									
All women living with HIV, born 
between 1942 and 1989, living in 
the counties of Stockholm and 
Gothenburg sometime between 
1983 and 2014 (n=1926) 	
Diagnosed with CIN2+  
        1983-2014 (n=179) 
No CIN2+ diagnosis  
          1983-2014 (n=1747) 	
All HIV-negative women, born 
between 1942 and 1989, living in 
the Counties of Stockholm and 
Gothenburg sometime between 
1983 and 2014 (n=1 189 835) 	
No CIN2+ diagnosis  
          1983-2015 (n=1 093 108)	
Diagnosed with CIN2+  
        1983-2015 (n=96 727)	
Not randomly selected for 
inclusion (n=96 406)	Randomly selected, matched for country of birth (n=321)	
HIV-negative women 
Women living with HIV 
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women. A medical record review was also performed for all women included in Paper III to 
collect information that was not registered in the registries. Variables collected included 
mode of treatment of CIN2+, radicality of conization performed, nativity and history of 
smoking. 
 
5.2 ANALYSIS 
 
Regions of birth 
For Paper I included women were classified into four regions of birth; Sweden, Sub-Saharan 
Africa, East (Eastern Europe and Central Asia and Asia and Pacific) and Other, using 
UNAIDS classification148. 
For Paper II included women were classified into six regions of birth: Sweden, Sub-Saharan 
Africa, Eastern Europe and Central Asia, Asia and Pacific, Latin America and Caribbean 
and Other (Western Europe except Sweden, Canada, USA, North Africa, and Middle East). 
Women with an unknown country of birth were analysed together with women of birth 
region Other, as Other/unknown.  
For Paper III and IV included women were classified into six regions of birth: Sweden, 
Western Europe except Sweden, Eastern Europe and Central Asia, Sub-Saharan Africa, Asia 
and Pacific, and Latin America and Caribbean. 
 
The CD4+ trajectory model 
For Paper II we applied a CD4+ trajectory model to estimate the time of HIV acquisition. 
The model extrapolates the CD4-cell decline backwards from the CD4 count at diagnosis to 
estimate a probable date of HIV-transmission. This method was first developed by Public 
Health England in collaboration with the European Centre for Disease Prevention and 
Control (ECDC) in 2012 and has later been revised and improved149,150. The model is based 
on a large group of British HIV-seroconverts (where time of seroconversion was known 
because of frequent HIV-testing among people at risk), whereby an algorithm was designed 
to estimate the time of HIV-seroconversion, based on factors associated with the intercept 
and the slope of CD4-cell decline. Region of birth and age, both known to affect CD4-cell 
decline, are adjusted for in this model. 
After applying the CD4+ trajectory model, the time of estimated HIV-seroconversion for 
each included woman was divided into three estimates: the earliest probable time of 
seroconversion, the average probable time, and the latest probable time.  
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HPV-genotyping analysis 
Collection of archived cervical material and sectioning 
For Paper IV all archived diagnostic slides from cervical biopsies/conizations of included 
women were retrieved and reviewed by a senior pathologist to reconfirm histological 
diagnosis. Formalin-Fixed-Paraffin-Embedded (FFPE) blocks from cervical 
biopsies/conizations of confirmed cases of CIN2+ were then collected from the bio banks 
where samples are stored in local pathology laboratories. All cases were subsequently 
sectioned at accredited laboratories, according to a contamination-proof procedure151. The 
first and last sections for each case were stained with haematoxylin and eosin (H&E-staining) 
for later re-review if needed. In between each case-block, a blank-block was sectioned as 
contamination control.  
DNA extraction and genotyping   
All sections, blank-blocks and case blocks, were extracted with a xylene-free method and 
HPV genotyped using polymerase chain reaction (PCR) with modified general primers 
(MGP)-PCR (primer targeting L1) and hybridization with type-specific probes in 
Luminex151,152. Forty-two beads, encompassing 37 different HPV-types, 3 HPV variants, and 
two “universal” HPV probes, were included in the Luminex. Luminex is a magnetic bead-
based multiplex immunoassay. The beads are fluorescently labelled, each with a distinct 
colour code to permit discrimination between different HPV-genotypes (Figure 9). 
 
Figure 9. HPV-type specific probes coupled to coloured beads.  
If the case was HPV-negative, extracted material from both the blank-block and case-block 
was diluted 1/10 and re-tested. Blank-blocks and the matched case-blocks were treated in 
exactly the same way during the whole process. All samples were analysed for beta-globin by 
quantitative real-time PCR to confirm sample adequacy153. The blank-block had to be 
negative for both HPV and beta-globin and the case-block positive for beta-globin. Cases that 
were beta-globin negative were classified as inadequate samples and were not analysed and 
neither were cases coupled to contaminated blank blocks (Figure 10). 
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Quantitative real-time PCR for HPV 16 and HPV 18  
Cases that were HPV negative in genotyping were analysed for the E6/E7 regions of the two 
common oncogenic HPV types, HPV 16 (primer targeting E7) and HPV 18 (primer targeting 
E6), using real-time PCR with one µL DNA used in both essays with a total volume of 25 
µL63.  
The laboratory was blinded to the identity of the samples and whether samples were from 
WLWH or HNW. 
 
Figure 10. Camilla (co-author paper IV) preparing for HPV-genotyping.  
 
Definition of outcomes 
For Paper I the main outcome was CIN3+, defined as CIN3, adenocarcinoma in situ or 
invasive cervical cancer. In a separate analysis main outcome was defined as CIN2+. 
Inclusion-date for WLWH was defined as the 1st of January 1993, date of HIV diagnosis or 
when the subject turned 18 years, whichever came last. Inclusion-date for HNW was defined 
as the 1st of January 1993 or when the subject turned 18 years, whichever came last. All 
subjects were followed from inclusion date until diagnosis of CIN3+ (or in a separate analysis 
CIN2+), last registered cervical cytology/biopsy or December 31, 2011, whichever happened 
first. Only histological results were used for assessing the outcome. 
For Paper II the main outcome was proportion of undiagnosed HIV among women 
diagnosed with or without CIN2+. After linking the study population to InfCare HIV, all 
women with CIN2+ diagnosed before HIV diagnosis and all women with a normal or mildly 
abnormal (defined as any of: CIN1, atypical squamous cells of undetermined significance, 
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atypical glandular cells, atypical cells of uncertain origin) cervical cytology or histology 
before HIV diagnosis were identified. After applying the CD4+ trajectory model, the time of 
estimated HIV acquisition for each included woman was divided in three estimates: the 
earliest probable time of acquisition, the average probable time, and the latest probable time. 
A woman was defined as having an undiagnosed HIV at the time of CIN2+ diagnosis if 
CIN2+ was diagnosed sometime between the year of the earliest probable date of HIV 
acquisition and the date of HIV diagnosis. Women diagnosed with CIN2+ before the year of 
the earliest probable date of HIV acquisition were excluded. 
For Paper III the main outcome was treatment failure defined as presence of CIN2+ on 
cervical cytology/histology at initial follow-up, within one year after treatment of CIN2+. 
Women with normal cervical cytology/histology at follow-up were considered successfully 
treated and were included in analysis of recurrence, defined as subsequent CIN1+. These 
women were followed from date of first follow-up after treatment of CIN2+, until date of 
recurrence, or if no recurrence took place, until date of last registered cervical 
cytology/histology. 
For Paper IV the main outcome was HPV genotype detected in women diagnosed with 
CIN2+ depending on HIV status. 
 
Statistical analysis 
Table 3. Summary of statistical analysis of included papers. 	 Study	design	 Measures	 Statistical	Methods	
Paper	
I	
	Cohort.		
	HNW	were	matched	to	WLWH	by	age	and	region	of	birth.			
	Cumulative	incidence	of	CIN3+.	
	Incidence	rate	of	CIN3+.	
	Hazard	ratio	(with	95%	CI)	of	CIN3+	in	WLWH	vs.	HNW.	
	Distribution	of	CD4	nadir	depending	on	outcome.		
	Cox	regression.	Stratified	for	age	at	inclusion,	calendar	year	at	inclusion	and	region	of	birth.	Adjusted	for	number	of	cervical	cytology	tests.	WLWH	alone	adjusted	for	CD4	count	at	inclusion	and	nadir	CD4.	
	Likelihood	ratio	test.	Interaction	test	for	HIV	status	and	birth	region.	
	Kernel	average	smoother	(nested	sub	analysis).		
Paper	
II	
	Case-control.		
	Un-matched.			 	Proportion	and	relative	risk	(with	95%	CI)	of	undiagnosed	HIV	in	women	with/without	CIN2+.	
	Chi-square	or	Fisher	test.	
	Wilcoxon	rank	sum	test.			
Paper	
III	
	Matched	cohort.		
	HNW	were	matched	to	WLWH	by	country	of	birth.			
	Odds	ratio	(with	95%	CI)	for	treatment	failure	in	WLWH	vs.	HNW.	
	Hazard	ratio	(with	95%	CI)	for	recurrence	in	WLWH	vs.	HNW.				
	Logistic	regression	to	estimate	effect	of	covariates	on	treatment	failure.	All	models	adjusted	for	age	(continuous,	at	time	of	treatment	of	CIN2+)	and	region	of	birth.	WLWH	alone	adjusted	for	HIV-RNA	level,	CD4	count	at	inclusion	and	CD4	nadir.		
	Cox	regression	to	estimate	effect	of	covariates	on	recurrence.	Same	adjustments	as	above.	
Paper	
IV	
	Case	only.		
	HNW	were	matched	to	WLWH	by	country	of	birth.		
	Prevalence	ratio.	Comparison	of	type-specific	HPV-genotype	prevalence	in	WLWH	vs.	HNW.		
	Poisson	regression.	All	models	adjusted	for	age	(continuous,	at	time	of	CIN2+	diagnosis),	grade	of	cervical	lesion,	and	region	of	birth.		
Abbreviations: CI: confidence interval, CIN3+: cervical intraepithelial neoplasia grade III, adenocarcinoma in situ and cervical cancer, 
CIN2+: cervical intraepithelial neoplasia grade II, grade III, adenocarcinoma in situ and cervical cancer, HIV+: living with HIV, HNW: 
HIV-negative, nadir CD4: lowest CD4 count ever measured for that individual, WLWH: women living with HIV. 
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In Paper I we calculated the incidence rate, cumulative incidence of CIN3+ as estimates for 
the absolute risk of CIN3+ (and in a sensitivity analysis CIN2+) in the studied cohort. 
Prevalent cases were excluded (CIN2+ diagnosed within 6 months of inclusion). Cox 
regression models, stratified for age at inclusion, calendar year at inclusion and region of 
birth, were used to estimate relative risks through hazard ratios (with corresponding 95% 
confidence intervals) of CIN3+ (and in a sensitivity analysis CIN2+) in WLWH compared to 
HNW. Adjustment was made for number of cervical cytology tests taken. Differences in 
hazard ratios between birth regions were tested for interaction (likelihood ratio test) between 
HIV status and birth region.  
In a sub analysis including only WLWH, hazard ratios of CIN3+ (and separately CIN2+) 
were estimated and adjusted for CD4 count at inclusion and nadir CD4. To illustrate the 
distribution of nadir CD4 in WLWH with or without CIN2+ (and separately CIN3+) a nested 
sub analysis was performed using a Kernel average smoother matched one-to one for age, 
birth region and time of follow-up.  
In Paper II the time of HIV acquisition was estimated using a CD4+ trajectory model 
(described above). We calculated the proportion and relative risk, with corresponding 95% 
confidence intervals (CI), of undiagnosed HIV in women with a diagnosis of CIN2+ 
compared to women with no diagnosis of CIN2+. Tests for significant differences in 
proportions were performed using the Chi-square test or, when numbers were small, the 
Fisher test. Differences in time to HIV diagnosis and level of nadir CD4 were tested for 
significance using Wilcoxon rank sum test. All other continuous variables were normally 
distributed and differences were calculated using the t-test. 
In Paper III logistic regression was used to estimate the effect of covariates (HIV-status, 
grade of cervical lesion, treatment modality, nativity, positive surgical margins and smoking) 
associated with treatment failure in all women and in WLWH only (suppressive ART and 
CD4 count at time of CIN2+ treatment, nadir CD4, mode of HIV-transmission and decade of 
HIV-diagnosis) through odds ratios (with corresponding 95% CI). Being highly dependent 
covariates, CD4 count and HIV-RNA levels (at time of treatment of CIN2+) were not 
adjusted for in the same model. All models were adjusted for age at time of treatment of 
CIN2+ and region of birth.  
Cox regression was used to estimate the effect of covariates on recurrence (with the same 
covariates as for treatment failure) through hazard ratios (with corresponding 95% CI). 
Schoenfeldt residual plots were used to ensure that the proportional hazards assumption was 
not violated. Suppressive ART was defined as HIV-RNA <50 copies/mL at time of treatment 
of CIN2+ (and in a sensitivity analysis <500 copies/mL).  
In a sub analysis only WLWH with suppressive ART were compared to HNW. In another 
sub analysis WLWH with more than 6 months suppressive ART at time of treatment of 
CIN2+ were compared to those with less than 6 months suppressive ART. 
In Paper IV type-specific HPV prevalence of specific HR HPV types detected in CIN2+ was 
compared between women with or without HIV. Prevalence ratios (PR) were calculated using 
generalized linear models (Poisson regression) with 95% CI. All models were adjusted for 
age (continuous, at time of CIN2+ diagnosis), grade of cervical lesion, and region of birth.  
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In order to estimate the proportion of cases of CIN2+ that might have been prevented by 
current HPV vaccines, the proportion of HR HPV types covered by the 2-valent/4-valent 
HPV vaccines (HPV 16 and/or 18) and the 9-valent HPV (16/18/31/33/45/52/58) vaccine was 
calculated.  
Calculations were done using STATA 13 software.  
 
Ethical considerations 
All four studies were approved by the Regional Ethical Review Board in Stockholm, Sweden 
(Diary numbers 2012/70-31/1 + 2012/1176-32+2013/2032-32+2015/1970-32+2016/1618-
32). The ethical board determined that, due to the population-based nature of the study, 
informed consent from study participants (including medical record review) was not required. 
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6 RESULTS  
 
Study population 
WLWH included in the final study populations (although different for all papers) included in 
this thesis were all dominated by migrants, around 70%. Most WLWH had acquired HIV 
heterosexually (>80%) and a majority had at one point been highly immunosuppressed with a 
median nadir CD4 < 200 cells/µl. 
6.1 PAPER I 
A total of 893 WLWH and 205 842 HNW contributed with 7587 and 2 815 303 years 
respectively and during that time 65 WLWH and 3129 HNW were diagnosed with CIN3+. 
Incidence of CIN3+ 
 
Figure 11. Paper I. Cumulative incidence of CIN3+ in women living with HIV (HIV+) and HIV-negative 
women (HIV-). 
We found the incidence of CIN3+ to be higher in WLWH than in HNW. After 18 years of 
follow-up the cumulative incidence (CuI) of CIN3+ was 13.1% (95% CI 8.9-17.2) in WLWH 
vs. 2.1% (95% CI 2.0-2.2) in HNW (Figure 11). The incidence rate was 8.6 (95% CI 6.7-
10.9) vs. 1.1 (95% CI 1.1-1.2) per 1000 person years in WLWH and HNW, respectively. 
The highest incidence of CIN3+ was seen in WLWH born in the region classified as East 
(Eastern Europe & Central Asia and Asia & Pacific), which was dominated by women born 
in Thailand (70%). After eight years of follow up these women had a CuI of 14.1% (95% CI 
5.9-22.3) compared with a low CuI of 0.5% (95% CI 0.4-0.6) in HNW from the same region 
(Figure 12).  
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Figure 12. Paper I. Cumulative incidence of CIN3+ in women living with HIV (HIV+) and HIV-negative 
(HIV-) women by region of birth (Swe, Sweden; Sub, Subsaharan Africa; East, Eastern Europe & Central Asia 
and Asia & Pacific; Other). 
 
Risk of CIN3+  
We found WLWH to have almost nine times higher risk of CIN3+ than HNW (HR 8.8, 95% 
CI 6.9-11.3). There was a significant interaction between being HIV-infected and birth region 
(p = 0.024), with the least difference in risk seen between WLWH and HNW born in Sweden.  
Risk of CIN3+/CIN2+ in WLWH only 
A CD4 count at inclusion above 349 was shown to be protective against both CIN3+ (CD4+ 
200-349: HR 0.58: 95% CI 0.29-1.15; CD4+ 350-500: HR 0.40: 95% CI 0.18-0.94; CD4+ > 
500: HR 0.48: 95% CI 0.23-0.98 vs. CD4+< 200: HR 1.0, ref) and CIN2+ (see paper I). 
Decreasing nadir CD4 count was significantly associated with CIN2+ only (p = 0.0001), 
graphically illustrated in a nested sub analysis (Figure 13). 
WLWH born in the East region (70% from Thailand) had more than two times higher risk of 
CIN3+ compared with WLWH born in Sweden (HR 2.5: 95% CI 1.22-5.02). When adjusting 
for nadir CD4 (HR 2.4: 95% CI 1.16-4.76) and CD4 at inclusion (HR 1.78: 95% CI 0.80-
3.94) the increased risk remained, although non-significantly for the latter adjustment. 
As the prevalence of current or prior ART at time of inclusion was very low (9%), adjustment 
for time on ART or time with suppressive ART was not performed in paper I. 
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Figure 13. Paper I. The distribution of nadir CD4+ T-cell count/µL in HIV-infected with an outcome of 
CIN2+ compared with HIV-infected with no outcome in a nested sub-analysis, matched for age (5-year 
interval), birth region and time of follow-up. The area under the curve shows the fraction of cases with an 
outcome of CIN2+ (or no outcome) that had nadir CD4 counts within a given interval. 
 
Registered cytology tests 
WLWH had a median number of registered cytology tests of one (interquartile range [IQR] 1-
4) during a median follow-up of seven years, while HNW had a median number of 4 tests 
(IQR 2-7) during a median follow-up of 15 years. Adjustment for number of registered tests 
made no difference to our results (data not shown). 
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6.2 PAPER II 
A total of 960 577 women were included out of whom 62 874 had at least one registered 
diagnosis of CIN2+ and of these women 175 were diagnosed with CIN2+ after HIV 
diagnosis and 62 653 had no HIV diagnosis (Figure 14). After applying the CD4+ trajectory 
model, 38 women were defined as having had undiagnosed HIV at the time of CIN2+ 
diagnosis (Figure 14). 
 
  
Figure 14. Paper II. Flowchart of the study population.  
 
The proportion of undiagnosed HIV was higher in women with CIN2+ than in women 
without but did not reach the threshold of 0.1% (Table 4). Among migrants, the proportion of 
undiagnosed HIV was also higher among women with CIN2+ than among women without 
and exceeded 0.1% (Table 4).  
Women with undiagnosed HIV at the time of CIN2+ had a significantly lower nadir CD4 
count compared with women without CIN2+ (median nadir CD4 95 cells/µl vs. 210 cells/µl; 
P < 0.01). Women born in the birth region Asia and Pacific, dominated by Thai women 
(80%), had a particularly low median nadir CD4 count when HIV was undiagnosed at the 
time of CIN2+ compared with women born in the same region without CIN2+ before HIV 
diagnosis (25 cells/µl vs. 180 cells/µl; P < 0.01). 
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Table 4. Paper II. Proportion [% (95% CI)] of undiagnosed HIV at the time of CIN2+ compared with 
women with no CIN2+.  
 
 
 
  
		
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Undiagnosed HIV 
at time of CIN2+ 
% (95% CI) 
Undiagnosed HIV 
and no CIN2+ 
% (95% CI) 
P-value 
All 0.06 (0.04-0.08) 0.04 (0.04-0.04) 0.017 
Migrant 0.30 (0.20-0.43) 0.08 (0.07-0.10) <0.001 
Sweden 0.02 (0.01-0.04) 0.02 (0.02-0.02)   0.29 
Sub-Saharan 
Africa 3.64 (2.24-5.80) 0.71 (0.60-0.84) <0.001 
Eastern Europe  
& Central Asia N/A   0.01 (0-0.02) N/A 
Asia & Pacific 0.71 (0.36-1.35) 0.13 (0.10-0.18) <0.001 
Latin America  
& Caribbean 0.22 (0.04-0.87) 0.05 (0.03-0.10) 0.035 
Other/unknown N/A 0.01 (0.01-0.02) N/A 
Thailand 2.02 (0.94-4.10) 0.57 (0.41-0.78) <0.001 
Ethiopia  5.26 (2.16-11.57) 0.85 (0.60-1.19) <0.001 
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6.3 PAPER III 
 
Figure 15. Paper III. (a) Flowchart of WLWH included in the study population. 
 
Figure 16. Paper III. (b) Flowchart of HIV-negative women included in the study population. 
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A total of 140 WLWH and 284 HNW were included in the final study population (Figure 15, 
Figure 16). Sixty-five percent of WLWH were on at least three antiretrovirals at time of 
treatment of CIN2+ and 53% on suppressive ART. 
Among included women, 21% of WLWH and 7% of HNW had treatment failure defined as 
CIN2+ at first follow-up. Thus, WLWH were more than three times more likely to have 
treatment failure after treatment of CIN2+ than HNW (OR 3.7: 95% CI 2.0-6.8) (Table 5). 
Grade of lesion but not treatment modality or nativity was significantly associated with 
treatment failure in logistic regression analysis.  
Suppressive ART (HIV-RNA < 50 copies/mL) was associated with reduced likelihood of 
treatment failure (OR 0.3: 95% CI 0.1-0.8) and this remained after adjusting for nadir CD4 
count (Table 5). 
Table 5. Paper III. Characteristics associated with treatment failure. 
CIN2+ at follow-up Odds ratio (95% CI) 
WLWH vs. HNW 3.7 (2.0-6.8) 
WLWH vs. HNW, adjusted for grade of initial lesion 3.9 (2.1-7.2) 
WLWH with suppressive ART vs. HNW 1.8 (0.8-4.2) 
Only WLWH  
Suppressive antiretroviral therapy  
Suppressive ART (defined as HIV-RNA<50) vs. HIV-RNA >50 copies/ml 0.3 (0.1-0.8) 
Suppressive ART (defined as HIV-RNA<500) vs. HIV-RNA>500 copies/ml 0.3 (0.1-0.7) 
Suppressive ART vs. HIV-RNA >50, adjusted for nadir CD4 count  0.3 (0.1-0.7) 
Suppressive ART >6 months vs. <6 months 1.1 (0.3-5.3) 
Suppressive ART >6 months vs. <6 months, adjusted for nadir CD4 count  1.1 (0.2-5.1) 
CD4 count, cells/µL  
<200 8.5 (2.3-30.7) 
200-349 0.9 (0.2-4.0) 
350-499 1.3 (0.3-5.1) 
≥500 1 (ref) 
Nadir CD4 count, cells/µL  
<200 6.5 (0.8-53.6) 
200-349 2.7 (0.3-26.0) 
 ≥350 1 (ref) 
Nadir CD4 count <200 compared to ≥350, adjusted for CD4 count (cont.) 2.9 (0.3-27.9) 
Estimated through odds ratios in WLWH compared with HNW, controlled for age and region of birth. 
  34 
Advanced immunosuppression (CD4 count < 200 cells/µl) at time of treatment of CIN2+ was 
associated with more than eight times higher odds ratio of treatment failure compared with 
CD4 count ≥ 500 (OR 8.5: 95% CI 2.3-30.7). Meanwhile, level of nadir CD4 count was not 
significantly associated with the likelihood of treatment failure. When adjusting for CD4 
count at inclusion and nadir CD4 count in the same model the association between level of 
nadir CD4 count and treatment failure decreased even more (Table 5). 
Of the 304 women included in the analysis of recurrence (defined as CIN1+), 13 out of 77 
(17%) WLWH and 10 out of 227(4%) HNW where defined as having recurrence. WLWH 
were five times more likely to recur (hazard ratio 5.0, 95% CI 2.1-11.6). The only statistically 
significant variable associated with recurrence, in Cox regression analysis, was CD4 count 
(continuous) at time of treatment of CIN2+ (Ptrend=0.0347).  
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6.4 PAPER IV 
In this interim analysis 68 WLWH and 127 HNW had valid HPV genotype results out of 
which 64 (94%) WLWH and 116 (91%) HNW were HPV positive. Fifty-nine percent were 
on at least three antiretroviral drugs at the time of CIN2+ diagnosis and 47% on suppressive 
ART (defined as HIV-RNA <50 copies/mL). 
Single HPV infections  
Although HPV 16 was the most common single HR HPV infection of both WLWH (22%) 
and HNW (43%), WLWH were less likely to be infected with HPV 16 than HNW (PR = 0.6, 
95% CI: 0.35-0.97, Table 6). HPV 35 was the second most common single HR HPV 
infection in WLWH (11%) compared to HNW (3%) (PR = 4.0, 95% CI: 0.94-16.67). Most 
WLWH with HPV 35 were born in sub-Saharan Africa (5/7). Both HPV 18 and 45 were less 
common than expected in both WLWH and HNW (Table 6). 
Table 6. Comparison of HPV genotypes detected in HPV-positive women diagnosed with 
CIN2/CIN3/AIS/ICC stratified by HIV status.  
 WLWH 
n (%) 
HNW 
n (%) 
Prevalence ratio1 
(95% CI) 
Any positive HPV 64 116  
HR single (group 1/2A2)    
HPV 16  14 (22) 50 (43) 0.6 (0.35-0.97) 
HPV 35 7 (11) 3 (3) 4.0 (0.94-16.67) 
HPV 18 2 (3) 3 (3) 1.0 (0.16-6.99) 
HPV 45  2 (3) 3 (3) 1.2 (0.19-7.16) 
HPV 33 2 (3) 7 (6) 0.6 (0.12-2.50) 
HPV 52 2 (3) 7 (6) 0.5 (0.09-2.43) 
HPV 31 2 (3) 7 (6) 0.5 (0.12-2.02) 
HPV 58 2 (3) 1 (1) 3.8 (0.34-41.44) 
HPV 51 2 (3) 1 (1) 3.0 (0.21-42.39) 
HPV 39 - - - 
HPV 56 - - - 
HPV 59 - - - 
HPV 68 - - - 
Multiple HPV    
1/2A and/or 2B and/or benign 28 (44) 26 (22) 2.0 (1.30-3.10) 
Multiple including ≥ 1 HR HPV 27 (42) 25 (22) 2.0 (1.27-3.13) 
Any multiple HR HPV (HR+HR) 18 (28) 15 (13) 2.1 (1.17-3.79) 
Multiple HR including HPV 16 6 (9) 9 (8) 1.2 (0.46-3.22) 
Multiple HR including HPV 18 2 (3) 1 (1) 2.4 (0.35-16.58) 
Multiple HR non HPV 16/18 (HR+HR) 10 (16) 5 (4) 3.7 (1.39-9.78) 
Potential HPV vaccine coverage    
HPV 16/18 alone4 
(bivalent vaccine) 16 (25) 55 (47) 
0.6 (0.38-0.97) 
crude 0.5 (0.33-0.84) 
At least one of HPV 16/18  26 (41) 69 (59) 0.7 (0.53-1.02) crude 0.7 (0.49-0.95) 
HPV 16/18/31/33/45/52/58 alone4 
(9-valent vaccine) 33 (52) 93 (80) 
0.7 (0.53-0.88) 
crude 0.6 (0.50-0.83) 
At least one of 16/18/31/33/45/52/58 47 (73) 103 (89) 0.9 (0.73-1.02) crude 0.8 (0.7-0.98) 
Numbers are n (% of any positive HPV). Percentages do not always add up to a hundred due to rounding. 
1Prevalence ratio (PR) (HIV-infected versus HIV-negative women) calculated using Poisson regression 
analysis, adjusted for age, grade of lesion and region of birth. 2 1/2A including HPV 
16/18/31/33/35/39/45/56/58/59/68. 3 2B including 26, 30, 53, 66, 67, 69, 70, 73, 82. 4Single or multiple 
infections with specified genotypes only. 
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Multiple HPV infections  
Multiple infections with at least one HR HPV genotype were significantly more common in 
WLWH (42%) than in HNW (22%) (PR = 2.0, 95% CI 1.27-3.13) and so were multiple 
infections with two or more HR HPV genotypes (PR = 2.1, 95% CI 1.17-3.79, Table 6). 
WLWH were more likely to have multiple HR HPV infections not including HPV 16 or 18 
than HNW (PR = 3.7, 95% CI 1.39-9.78). 
HPV types represented in current HPV vaccines 
Only 25% of WLWH vs. 47% of HNW had HR HPV types that are covered by the 2-valent 
and 4-valent HPV vaccines (HPV 16 and/or 18) (PR = 0.6, 95% CI: 0.38-0.97). Even HR 
HPV types covered for by the 9-valent HPV vaccine (16/18/31/33/45/52/58) were 
significantly less frequent in WLWH (52%) compared to HNW (80%) (PR=0.7, 95% CI 
0.53-0.88, Table 6). When assuming that lesions with multiple infections, including HPV 
16/18 are caused by the latter there was no longer a significant difference between WLWH 
compared to HNW (Table 6). 
A more severe grade of cervical lesion was associated with the likelihood of having genotype 
16/18 (PR for CIN3 = 2.1, 95% CI 1.26-3.54, PR for invasive cancer 3.5, 95% CI 2.11-5.93, 
ref CIN2) and with genotypes covered for in the 9-valent vaccine  (PR for CIN3 = 1.36, 95% 
CI 1.07-1.73, PR for invasive cancer 1.57, 95% CI 1.22-2.05, ref CIN2) but when adjusting 
for grade of lesion the PRs associated with HIV-status changed only slightly (Table 6). 
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7 DISCUSSION 
 
The global prevalence of WLWH varies greatly with different regions and it is estimated that 
around 80% of WLWH are presently living in SSA and 10% in Asia and Pacific35. In the 
same regions we see the highest burden of cervical cancer because of poor access to cervical 
cancer screening and higher risk when living with HIV12. 
The study populations of WLWH included in this thesis, although different for all four 
papers, represent this global disparity well with its domination of migrants, among whom 
70% were born in SSA and 10 to 20% in Asia and Pacific. Most previous studies in this field 
have been based on populations living in the US and lately SSA but studies based in Europe 
are scarce and studies based on migrants living in Europe even fewer77,124,154. Uniquely for all 
four registry-based studies included in this thesis, we have had access to data regarding 
country of birth also for included HIV-negative women. This has made it possible for us to 
control for country of birth that may otherwise cause confounding in a study population based 
on migrants. Most importantly this has made our results relevant not only to Sweden or 
Western Europe but also to the global regions where the burden of HIV and cervical cancer is 
the greatest. 
Regarding the risk of high-grade cervical lesions and outcome after its treatment  
Earlier studies have found a 2 to 4-fold increased relative risk of CIN2+/CIN3+ in WLWH 
compared to HNW10,93,106,124,155. In Paper I we found WLWH to have more than eight times 
higher risk of CIN3+ than HNW and more than nine times higher risk of CIN2+, which was 
thus higher than expected and driven by the large difference in risk between migrants living 
with and without HIV (more on that below). We found only one case of ICC in WLWH 
during follow-up. Earlier studies have found the absolute risk of invasive cervical cancer in 
WLWH to be very small when these women are included in cervical cancer screening 
programs123,124.  
As expected WLWH were more likely to have treatment failure after treatment of CIN2+ 
than HNW104,110,113 (Paper III). This was true even when restricting the definition of 
treatment failure to CIN2+ which contradicts the suggestion that increased treatment failure 
in WLWH is mainly due to new HPV infections contracted after treatment104. We found 
WLWH to be five times more likely to recur than HNW, although these results should be 
interpreted with a little caution. There were only 13 cases of recurrence in WLWH and of 
these a majority where CIN1 so this could in fact, with reference to the discussion above, be 
due mainly to new HPV-infections rather than true recurrence of neoplastic lesions. 
Regarding the role of immunosuppression 
Similar to previous studies we found advanced immunosuppression to be associated with 
both CIN3+ (Paper I) and treatment failure (Paper III)10,104,106,110,115,124,156. In both Paper I 
and Paper III the level of immunosuppression as measured by CD4 count at 
inclusion/treatment of CIN2+ was more robustly associated with outcome (CIN3+/treatment 
failure) than nadir CD4. When adjusting for CD4 count at inclusion and nadir CD4 in the 
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same model in Paper III the association between level of nadir CD4 and treatment failure 
decreased even more. This could indicate that present CD4 count is a better predictor of 
future outcome than the level of CD4 in the past, contrary to what has been stipulated in at 
least one earlier study156. However, as almost all WLWH included had at one point been 
highly immunosuppressed (about 60% had nadir CD4 <200 in both Paper I and Paper II 
and almost 90% had nadir CD4 <350 in both Paper I and Paper II) we may not have been 
able to show an association for this variable even if there was one.  
Regarding the role of ART 
Even though it has been known for quite some time that HIV-related immunosuppression is 
associated with increased risk of persistent HPV and the subsequent development of CIN and 
ICC, the role of ART on these processes has been uncertain. It is only recently that ART has 
been proven to be associated with reduced prevalence of HR HPV and reduced incidence of 
HSIL/CIN2+/ICC78. To our knowledge, Paper III is the first study to find suppressive ART 
associated with effective treatment of CIN2+. A majority of earlier studies has not had access 
to HIV-RNA levels and used only self-reported use of ART with the risk of reporting 
bias104,110,115. A small study finding less recurrence (defined as treatment failure in our study) 
in those on self-reported ART used no measure of effect analysis157. One study having access 
to HIV-RNA levels did not find the HIV-RNA level associated with treatment failure, but 
unlike ours that study included women treated for CIN1, which is usually self-healing and not 
recommended to treat114.  
It is believed that the main benefit of ART, in this setting, is the consequential increase of 
non-impaired CD4-cells that are needed to clear the HPV-infection. But although it is widely 
accepted that effective immune control is required to prevent persistent HPV infection, later 
studies indicate that chronic inflammation and misguided immune responses may also play an 
important role in HR HPV-induced carcinogenesis, even in HIV-negative individuals158.  
It has been suggested that in the early stages of HR HPV-induced carcinogenesis the HR 
HPV-infected cells suppress acute inflammation in the epithelium, while later on HR HPV-
transformed cells initiate chronic stromal inflammation, led by an increase of IL-6158. 
Meanwhile, as mentioned earlier, HIV-infection is associated with persistent immune 
activation and inflammation, illustrated by increased levels of immunologic biomarkers (such 
as IL-6) that remain increased even after ART is initiated, although at lower levels28,158-161. 
Thus, HIV-induced inflammation, not only reduced CD4 counts, may play an important role 
in cervical cancer development in WLWH and this role may be diminished although not 
eradicated with suppressive ART. This could explain why we found WLWH with suppressed 
ART to still have increased (though not statistically significant) likelihood of treatment 
failure compared to HNW (OR 1.8: 95% CI 0.8-4.2).  
Regarding regional differences  
Unexpectedly, WLWH born in the East region (70% Thai) had more than two times higher 
risk of CIN3+ compared with WLWH born in Sweden (Paper I). If anything one would have 
expected a higher risk in WLWH born in SSA where the global burden of cervical cancer is 
the highest but we saw no statistical difference between these women and women born in 
Sweden. We considered the possibility that WLWH born in East were more 
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immunosuppressed, due to late HIV-diagnosis (as seen in Paper II), which would have 
increased their risk of CIN3+. However, when adjusting for nadir CD4 and CD4 count at 
time of inclusion the increased risk remained, although non-significantly for the latter 
adjustment. One reason could be that sexual history differs depending on region of birth with 
perhaps increased lifetime HPV exposure in WLWH from the East region.  
Regarding HPV genotypes associated with high-grade cervical neoplasia 
We found HPV 16 to be the most common single infection detected in all women irrespective 
of HIV-status, although, as expected from earlier studies, the proportion of HPV 16 was 
lower in WLWH than in HNW (Paper IV)69,162. Women from SSA have previously been 
found to have the lowest proportion globally of HPV 16 positivity in all grades of cervical 
lesions and these interim results support this observation88. Meanwhile, a recent US study 
found a lower HPV 16 prevalence in CIN3+ in African American compared to Caucasian 
WLWH, indicating a genetic association rather than a geographic one163. 
It is believed that immune competent individuals control non-HPV 16 better than HPV 16, 
but that with increasing immunosuppression the proportion of non-HPV 16 genotypes 
increases among persistent HR HPV infections83. The increased prevalence of non-HPV 16 
(i.e. less carcinogenic HR HPVs) detected in WLWH diagnosed with CIN2/CIN3 may 
explain why although cervical cancer is increased in WLWH the absolute risk is not as great 
as for other virally associated AIDS-defining cancers such as Kaposi sarcoma or non-
Hodgkin lymphoma32,81,164.  
In Paper IV we found HPV 35 to be the second most common single infection in WLWH. A 
majority of WLWH with HPV 35 were born in SSA. This is in line with earlier studies that 
have shown an increase of HPV 35 detected in all grades of cervical lesions in women born 
in SSA, compared to other regions of the world, in both HNW and WLWH69,88. A recent 
study, based in SSA, found persistent HPV 35 (and 56) to be the non-vaccine types most 
commonly associated with incident CIN2+ and a meta-analysis based on WLWH diagnosed 
with ICC in SSA found HPV 35 to be the fifth most commonly detected genotype84,165. These 
findings suggest that adding HPV 35 to future HPV vaccines should be considered84.  
The detection of single HPV 18 was lower than expected in all women but especially in 
WLWH, as previous studies have shown that these women are more likely than HNW to be 
diagnosed with ICC caused by HPV 1884,166. Neither did we see an increase of HPV 45 
despite this genotype being previously identified as an important HR HPV type in WLWH in 
SSA and considering that women born in SSA dominated this study. One reason for this may 
be the few cases of ICC that were included in this interim analysis. It has been suggested that 
the carcinogenicity of HPV 18/45 is underestimated in studies based on CIN2/CIN3, rather 
than ICC, as the increase of HPV 18/45 is mainly seen in the interim between the 
development of CIN3 to ICC88. 
Similar to earlier studies we found WLWH to be significantly more prone to have multiple 
HR HPV infections than HNW167-169. The clinical significance of multiple infections is 
unclear as prospective evidence on this issue is limited170. A US study with long-term follow-
up did not find multiple HPV infections associated with an increase of CIN3+. In another 
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study, including only HNW, co-infection with both low and high-risk HPV was even 
associated with a reduced risk of future invasive disease and slower progression to ICC86,87.  
Regarding HPV vaccination 
It is a concern that among WLWH in Paper IV only one quarter had HR HPV genotypes that 
would be covered by the 2 and 4-valent vaccines and only half had genotypes covered by the 
9-valent vaccine. These are lower estimates than what was seen in a recent study based on 
WLWH with CIN2/3 in Burkina Faso and South Africa (around 40% covered by the 2/4-
valent and 80-90% by the 9-valent) and an earlier South African study (42% covered by the 
2/4-valent) including women diagnosed with HSIL101,165.  
A recent meta-analysis, including studies based in SSA indicated that about 60% of WLWH 
with ICC would have been covered by the 2 and 4-valent vaccines and about 80% by the 9-
valent vaccine84. If our study had included only ICC we would probably have detected a 
higher proportion of HPV 16/18166. Although the main target for HPV vaccination is ICC, a 
diagnosis of CIN2/CIN3 will in most cases lead to treatment (usually conization), which is 
associated with complications such as preterm birth129. In addition, as shown in Paper III, 
WLWH are more likely to have treatment failure after treatment of CIN2/CIN3. Given the 
findings in Paper IV it would seem that young PLWH and populations at-risk for HIV, not 
the least those living in SSA, would benefit more from the 9-valent vaccine than the 2 and 4-
valent vaccines. Nevertheless, the extra protection provided by the 9-valent vaccine will not 
make any difference in LMIC if access is limited by cost and poor infrastructure as in many 
places today171 
Regarding cervical cancer screening 
In Paper I we found a low adherence to cervical cancer screening in WLWH. To ensure that 
this was not because of poor registration in NKCx, we reviewed 100 randomly selected 
medical records from these women and found that nine percent had cervical cytology tests 
that were not registered in NKCx. This, however, would only partly explain our findings. One 
reason for low attendance to cervical screening may be that while routines for screening 
HNW have been very well implemented nationally, the more frequent screening of WLWH is 
not automatized in the same way and quite often dependent on the awareness of midwives, 
gynaecologists and HIV-clinicians which may vary between clinics. 
Until recently, most high-income countries recommended WLWH to be screened with 
cervical cytology twice during the first year after HIV-diagnosis followed by annual testing 
until the age of 64. This has also been the recommendation in Sweden for the time period 
included in this thesis. With increasing knowledge about HPV and HIV co-infection, several 
guidelines are now leaning towards having the same/or more similar HPV-based screening 
programs for women independent of HIV-status112,125-127. This may not only increase the 
adherence to the screening program in WLWH but also decrease costs and reduce risk of 
harm (such as anxiety after slightly abnormal results and higher risk of pre-term births after 
conization) caused by possible over diagnosis and overtreatment129.  
The risk of developing CIN2+ is low in women with a negative HR HPV-test irrespective of 
HIV status 99. In Sweden, HPV testing of women includes all HR HPV types, but triaging for 
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only HPV 16/18 is often recommended, especially in low resource settings11,122,172. In Paper 
IV we found that WLWH had a high proportion of non-HPV 16/18 in CIN2+ biopsies, 
women who would thus not be identified as at risk of developing CIN2+ if screening 
included only HPV 16/18. Meanwhile WLWH who are HPV-positive with normal cervical 
cytologies have a very high prevalence (>70%) of non-HPV 16/18 infections69. The question 
therefore remains whether to include HR HPV other than HPV 16/18 in HPV-based cervical 
cancer screening in WLWH with the risk of reducing the positive predictive value of this 
test128.  
Regarding high grade cervical neoplasia as an indicator disease for HIV 
Migrants in EU are at particular risk of late HIV-diagnosis and therefore more likely to 
present with advanced immunosuppression and disease i.e. have AIDS, at time of HIV-
diagnosis. A previous study found that one quarter of newly HIV-diagnosed patients in 
Sweden had presented for health care with typical HIV/AIDS associated conditions without 
being HIV-tested44. Late HIV-diagnosis is associated with higher mortality and morbidity as 
well as increased risk of HIV transmission and higher health-care costs44,173. Although 
indicator-guided HIV-testing has been recommended in Europe since 2013 it is not yet 
widely implemented44,54,174-176.  
In Paper II we found migrant women diagnosed with CIN2+ to have a prevalence of 
undiagnosed HIV exceeding the threshold estimated to be cost-effective for HIV-testing. It is 
very important to identify these women who are unaware of their HIV-status so they can 
initiate ART as soon as possible since they have, as shown in Paper III, better outcome after 
treatment of CIN2+ when on suppressive ART. 
It has been discussed over the past years among HIV-clinicians and gynaecologists whether 
or not to offer HIV-testing to all women in Sweden diagnosed with the indicator disease 
cervical dysplasia/cancer. There has been hesitancy among gynaecologists to single-out 
testing of migrants only, while at the same time scepticism as to the cost-benefit of HIV-
testing all women. Our results do not support HIV-testing all women diagnosed with CIN2+ 
in Sweden. However, future updated calculations may find HIV screening cost-effective at a 
lower prevalence than the presently suggested 0.1%, as the benefits of early ART have been 
clarified since the latest calculations of cost-effectiveness26,27,161.   
Even in migrants with no CIN2+, the prevalence of undiagnosed HIV was still quite high 
(0.08%) with a confidence interval including 0.1% and for women born in SSA and Asia & 
Pacific with no CIN2+ the prevalence was above 0.1%. Consequently, HIV testing all 
migrant women with unknown HIV-status at the time of cervical screening/gynecology 
check-up, irrespective of cervical cytology results, could be considered as these women have 
very much to gain from getting aware of their HIV-status as soon as possible. An earlier start 
of ART will, apart from as mentioned earlier reduce mortality, morbidity and transmissibility, 
more specifically decrease progression of SIL, increase SIL/CIN regression and reduce 
incidence of ICC78.  
Limitations of included studies 
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Limitations common for all four papers, or of particular interest, are discussed here. For 
detailed discussions on limitations see individual papers. 
Smoking is a known risk factor for the development of cervical cancer, but we were not able 
to adjust for smoking in these studies since smoking status only recently has been added to 
the InfCare HIV registry (Papers I, III, and IV) and although smoking is supposed to be 
recorded in medical records, this was most often lacking (Paper III)91. The number of 
current or former smokers in the Swedish HIV-cohort is lower compared to other HIV-
cohorts. In a recent (yet unpublished) survey including 717 WLWH (24% of WLWH 
currently living in Sweden) 14% were current smokers and 14% previous smokers40. This is 
in contrast to the number of current smokers among HIV-infected women in the US (50%) 
and in Denmark (43%)10,124. Current smoking was significantly associated with two times 
higher risk of CIN3+ in a US study, but there was no significant association with former 
smoking10. In Sweden, 9.6% of the female HIV-negative population (16-84 years old) are 
current smokers177. Given the low prevalence of smokers in the Swedish HIV cohort it is not 
likely that confounding by smoking explains our results. 
We did not have access to data regarding sexual history so we could not control for this 
variable. It is therefore not possible to exclude that the increased risk of CIN3+ seen in 
WLWH from the East region (Paper I) was due to higher lifetime HPV exposure than 
WLWH from other birth regions. Also we cannot disregard the fact that cases classified as 
recurrence after treatment of CIN2+ (Paper III) may instead be due to new HPV-infections. 
For Paper IV not all requested cervical blocks were sent from bio banks. In some cases the 
bio bank refused providing the material due to not-defined reasons, in other cases there was 
lack of tissue left in the block, or diagnostic slides needed for review were missing. This is 
not unique to our study and is evidently something that needs improving so that access to bio 
bank material can continue to be an essential part of Swedish research63. 
Strengths of included studies 
The national registry InfCare HIV is a virtually complete registry that is continually updated 
and the high quality of data is regularly assessed and confirmed. HIV-clinicians in Sweden 
have come to rely on InfCare HIV in the daily practice as a tool for explaining lab-results to 
patients as well as for making clinical decisions and are therefore highly motivated to update 
patient variables. Lab results (for example HIV-RNA) are automatically included in the 
registry and we were able to assess the effect of suppressive ART (Paper III), instead of as 
in most previous studies self-reported ART use. We have also been able to control for level of 
CD4 counts in all papers. 
For all four studies we have had access to data from NKCx, a highly functioning nationwide 
registry of cervical cytology and histopathology. The completeness of the registry is high (≥ 
90% for both cytology and histology) and based on both screening and colposcopy results 
irrespective of where the examination has taken place. In other studies in this field cervical 
screening history has often been self-reported which may lead to recall-bias. For Paper IV 
we included only biopsy specimens (rather than cytology), which enhances the accuracy of 
the HPV genotyping analysis and reduces the prevalence of multiple infections. 
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In summary, this thesis found that WLWH in Sweden have a larger than expected increased 
risk of high-grade CIN compared to HNW and that this was driven by a great discrepancy in 
risk between migrants with and without HIV. In WLWH, we found an unexplained difference 
in risk of CIN3+ depending on region of birth, remaining after adjusting for 
immunosuppression. WLWH in our study had more treatment failure and recurrence after 
treatment of CIN2+ than HNW, but high CD4 counts was protective of treatment failure. For 
the first time we showed suppressive ART to be associated with effective treatment of 
CIN2+. WLWH had less proportion of HPV 16 infection in histology-confirmed CIN2+ 
compared to HNW from the same country of birth and the proportion of WLWH with HR 
HPV types covered by current HPV vaccines was lower compared to HNW. Further, we 
found migrants diagnosed with CIN2+ to have a prevalence of undiagnosed HIV above the 
threshold estimated cost-effective for HIV-testing, indicating that this population should be 
HIV-tested. 
Early HIV diagnosis, access and adherence to ART, HPV vaccination of young people living 
with HIV and those at high-risk of HIV-infection, and finally access and adherence to 
cervical cancer screening are all of crucial importance to minimize the incidence of high-
grade CIN and its progression to ICC in women living with HIV.  
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8 CONCLUDING REMARKS 
 
In response to specific aims 
 
I       
• The cumulative incidence, incidence rate and risk of CIN3+ were substantially 
increased in WLWH compared to HNW, which was driven by a great discrepancy in 
risk between migrants with and without HIV. Among women living with HIV we saw 
clear differences in risk of CIN3+ depending on region of birth.  
II 
• The prevalence of undiagnosed HIV in all women diagnosed with CIN2+ in Sweden 
did not reach the level suggested cost-effective for HIV-testing. 
• The prevalence of undiagnosed HIV in migrant women diagnosed with CIN2+ in 
Sweden did reach the level suggested cost-effective for HIV-testing. 
III 
• WLWH had poorer outcome after treatment of CIN2+ than HNW. 
• Suppressive ART and high CD4 counts were both associated with better outcome 
after treatment of CIN2+ in WLWH. 
IV 
• The proportion of HPV 16 in CIN2+ biopsies was lower in WLWH than in HNW 
while the prevalence of multiple HR HPV infections was increased in WLWH.  
• Only one quarter of WLWH had HR HPV genotypes that would have been covered 
by the bivalent/quadrivalent HPV vaccine.  
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9 CONSIDERATIONS REGARDING CLINICAL 
IMPLICATIONS 
 
Immunosuppression was associated with the incidence of CIN2+ and with failure after 
treatment of CIN2+ in our study. To minimize HIV-related immunosuppression WLWH 
needs to be identified early, thus enabling an early start of ART.  
In Sweden, we need to ensure efficient HIV-testing at time of immigration. An enhancement 
of the implementation of HIV-indicator guided HIV-testing is needed and migrants diagnosed 
with CIN2+ should be offered HIV-testing. 
Adherence to ART is crucial in PLWH to reduce mortality, co-morbidity and HIV-
transmission. Suppressive ART was associated with effective treatment (conization) of 
CIN2+ in our study. The Swedish InfCare HIV cohort has one of the best HIV treatment 
results in the world, but globally continuum of care in HIV cohorts is a major issue and needs 
to be prioritized.  
Access and adherence to cervical cancer screening is essential for all women. International 
and Swedish guidelines now recommend similar or almost similar screening intervals 
irrespective of HIV status. 
WLWH had a reduced proportion of HPV 16 in CIN2+ biopsies compared to HNW in our 
study. In Sweden, HPV triaging includes all HR HPVs. Efficient, easy-to use and cheap HPV 
triaging is needed in regions with high prevalence of HIV and which HR HPVs should be 
included in HPV-triaging in these regions needs to be evaluated. 
The 9-valent HPV vaccine seems to be a better choice, than other current HPV vaccines, for 
the protection of CIN2+ in WLWH. Sweden has just recently decided to exchange the 4-
valent for the 9-valent vaccine in the national HPV vaccination program. 
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10 FUTURE PERSPECTIVES 
 
Cervical cancer is one of few cancers that is preventable if HPV vaccination and cervical 
cancer screening is combined. The main obstacle is to reach high global coverage of HPV 
vaccination and cervical cancer screening, especially in LMIC. For the prevention of high-
grade cervical intraepithelial neoplasia and its progression to cervical cancer in WLWH there 
are still large gaps of knowledge that needs to be filled. Two research questions of particular 
interest to me are:  
What is the efficacy of HPV vaccination in PLWH? 
As mentioned earlier, HPV-vaccines have been found to be safe and well tolerated in PLWH 
(children and adults) and do not alter the CD4 count or HIV viral load of those vaccinated 138-
141,178. The antibody response, however, is significantly lower in girls living with HIV relative 
to HIV-negative girls, especially when immunosuppressed, but whether this is a clinically 
relevant decrease remains uncertain142,144. Suppressive ART seems to predict a better 
antibody response179. To date there is very little data concerning the efficacy of HPV 
vaccination in PLWH145,180. The only efficacy study published this far found less persistent 
HPV in vaccinated girls/women living with HIV compared to unvaccinated WLWH145.  
There was no HNW comparison group in this study, which was relatively small (n = 279) and 
with only two years of follow-up. Large HPV vaccine efficacy studies, with long-term 
follow-up and with the statistical power to assess the effect of immunosuppression and 
suppressive ART, are highly needed in PLWH. 
What HR HPV-genotypes are associated with treatment failure after treatment of CIN2+ in 
WLWH? 
Data is scarce regarding which HR HPV genotypes are associated with HR HPV persistence 
after treatment of CIN2/CIN3 in WLWH. A Kenyan study (n = 85) with short-term follow-up 
(six months) found that cryotherapy eliminated three quarters of CIN2/3 but only one fifth of 
HR HPV infections in WLWH181. They did not find persistence of HR HPV associated with 
CD4 count or time on ART, which may have been due to lack of power. A US study 
(WLWH n = 170, HNW n = 15) found 67% of WLWH with treatment failure to have 
persistent HR HPV but they did not specify which genotypes were associated with treatment 
failure. More data, preferentially based on larger studies, is needed on HR HPV type 
persistence and its association with treatment failure and recurrence in WLWH treated for 
CIN2+. This is important for the implementation of evidence-based guidelines for post-
treatment follow-up in these women.  
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11 SVENSK SAMMANFATTNING (SWEDISH SUMMARY) 
 
Med tillgång till effektiv hivbehandling har dödligheten i hiv/aids minskat dramatiskt och 
förväntad livslängd närmar sig den för hivnegativa individer. Dock ser man bland individer 
som lever med hiv en ökad risk för att utveckla cancer.  
Det är välkänt att kvinnor som lever med hiv har en ökad risk för persistenta onkogena 
infektioner med humant papillomvirus (HPV) och därmed också en ökad risk att utveckla 
livmoderhalscancer och dess förstadier. Fram tills nu har det varit okänt hur förekomsten ser 
ut bland kvinnor som lever med hiv i Sverige. Syftet med denna avhandling var att analysera 
omfattningen av allvarliga förstadier till livmoderhalscancer (CIN2+/CIN3+) bland kvinnor 
som lever med hiv i Sverige, att bedöma vilka kvinnor som har störst risk för att utveckla 
CIN2+/CIN3+ och orsaken till detta (arbete I), hur utfallet är efter en behandlingsåtgärd av 
dessa förstadier (arbete III) samt vilka HPV-genotyper som orsakat dessa förstadier (arbete 
IV). Vi ville även undersöka om förstadier till livmoderhalscancer är att klassas som en 
indikatorsjukdom för hiv i Sverige d.v.s. om kvinnor som diagnostiseras med dessa 
cancerförstadier bör hivtestas (arbete II). 
Arbete I är en registerstudie där vi inkluderade 893 kvinnor som lever med hiv från det 
nationella hiv registret (InfCare HIV) och 205 842 hiv-negativa kvinnor från det svenska 
befolkningsregistret, frekvensmatchade efter födelseår och födelseregion. Studiepopulationen 
länkades sedan till det Nationella Kvalitetsregistret för Cervixcancerprevention (NKCx). 
Efter 18 års uppföljning hade hela 13 % av kvinnor som lever med hiv fått mycket allvarliga 
cellförändringar (CIN3+) jämfört med 2 % för hivnegativa, vilket motsvarar en mer än 8 
gånger ökad risk och var relaterat till graden av immunsvikt. Hivinfekterade med östlig 
födelseregion (dominerade av thailändska kvinnor) hade två gånger högre risk för CIN3+ 
jämfört med kvinnor som lever med hiv födda i Sverige, en risk som kvarstod efter justering 
för graden av nedsatt immunförsvar. Deltagandet i regelbunden screening för 
livmoderhalscancer var lågt för kvinnorna som lever med hiv, oavsett födelseregion.  
I arbete II utförde vi en registerstudie där vi inkluderade 960 577 kvinnor födda mellan 1940 
och 1990, boende i Stockholm eller Göteborg någon gång mellan 1990 och 2014, som hade 
minst ett registrerat cellprov i NKCx. Efter att ha länkat dessa kvinnor till InfCare HIV och 
analyserat sannolik tidpunkt för hivinfektion (med en s.k. trajektorisk CD4 modell) kunde vi 
uppskatta hur många kvinnor som hade en odiagnostiserad hiv vid tidpunkten för diagnos av 
CIN2+. Vi fann att förekomsten av odiagnostiserad hiv vid CIN2+ diagnos inte nådde den 
nivå (0.1%) då hivtest rekommenderas när vi tittade på alla kvinnor i studiepopulationen. 
Däremot hade migranter med konstaterad CIN2+ en förekomst av odiagnostiserad hiv på 
0.3% vilket indikerar att denna population bör hivtestas. 
Arbete III är en registerstudie där vi länkade InfCare HIV med det svenska 
befolkningsregistret och med NKCx. Vi inkluderade 179 kvinnor som lever med hiv med 
konstaterat förstadium till livmoderhalscancer (CIN2+) och matchade varje kvinna med två 
hivnegativa kvinnor, diagnostiserade med CIN2+, från samma födelseland. Kompletterande 
information hämtades från patientjournaler. Vi fann att efter behandling (konisering) av 
CIN2+ hade kvinnor som lever med hiv en mer än tre gånger ökad risk för utebliven läkning 
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och en fem gånger ökad risk för återfall. De kvinnor som lever med hiv som i vår studie hade 
en välfungerande hivbehandling vid konisering av CIN2+ hade en bättre chans till utläkning, 
vilket denna studie är först med att påvisa. Ett bra immunförsvar var även det kopplat till 
bättre chans till utläkning. 
I arbete IV studerade vi samma kvinnor som i arbete III men nu för att se om de HPV-
genotyper som orsakat CIN2+ hos dessa kvinnor skiljde sig åt beroende på om kvinnan lever 
med hiv eller ej. Vi fann att den HPV genotyp (16) som oftast orsakar livmoderhalscancer var 
mindre vanlig bland kvinnor som lever med hiv än bland de hivnegativa kvinnorna. Vi fann 
också att endast en fjärde del av kvinnor som lever med hiv jämfört med hälften av de 
hivnegativa kvinnorna hade onkogena genotyper som är inkluderade i det 2-valenta/4-valenta 
HPV vaccinet. Det 9-valenta HPV vaccinet tycks vara ett bättre val för ungdomar/kvinnor 
som lever med hiv och i populationer med hög risk att smittas med hiv. 
Sammanfattningsvis visar denna avhandling att kvinnor som lever med hiv i Sverige har en 
markant ökad risk för allvarliga livmoderhalsförändringar jämfört med hivnegativa och att 
födelseregion och grad av immunsvikt tycks påverka risken. Migranter med konstaterat 
allvarliga livmoderhalsförändringar bör hivtestas då denna population har en ökad förekomst 
av odiagnostiserad hiv. Kvinnor som lever med hiv har en ökad risk för att inte läka ut 
allvarliga livmoderhalsförändringar efter att ha genomgått behandling (vanligtvis konisering) 
av densamma men bättre chans till utläkning om de har en välfungerande hivbehandling. Det 
är av stor vikt att kvinnor som lever med hiv deltar i screening för livmoderhalscancer och 
ungdomar som lever med hiv bör HPV vaccineras. Det 9-valenta HPV vaccinet tycks vara ett 
bättre val än det 2-valenta/4-valenta HPV vaccinet för ungdomar/kvinnor som lever med hiv.  
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